Prevalence of HIV-associated neurocognitive impairment (hand) amongst adults aged 50 and over attending a HIV clinic in Northern Tanzania

Paddick, Stella-Maria; Kellet-Wright, J; Flatt, Aidan; Eaton, Patrick; Kisoli, Aloyce; Thornton, Jacqui; Irwin, Charlotte; McCartney, Judith; Yarwood, Vanessa; Walker, Richard; Dotchin, Catherine; Gray, William K.; Lwezuala, Bingileki; Mukaetova-Ladinska, EB; Akinyemi, Rufus; Urasa, Sarah

doi:10.1016/j.jns.2017.08.368

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Future studies may fill this gap. Moreover, Paddick [ 66 ] found that neurocognitive impairment is less associated with HIV infection, and its influencing factors are more similar to those associated with neurodegenerative dementia in PLWH aged 50 and above. In addition, HAND is more persistent and severe in older PLWH [ 67 ].…”

Section: Discussionmentioning

confidence: 99%

Antiretroviral therapy improves neurocognitive impairment in people living with HIV? A meta-analysis

Gao

Meng

Xiao

et al. 2020

International Journal of Nursing Sciences

View full text Add to dashboard Cite

Objectives Although effective antiretroviral therapy (ART) has been used for more than two decades, HIV-associated neurocognitive disorder remains prevalent. Thus, whether ART can improve neurocognitive impairment is controversial. This review aims to explore the effects of ART on cognitive impairment in people living with HIV (PLWH). Methods A systematic literature search was conducted in eight databases (PubMed, Embase, Web of Science, Cochrane Library, CNKI, VIP, China Biology Medicine disc, and WanFang) to identify studies that compare cognitive function between study groups who are administered and not administered ART. We searched for articles published up to April 2019. Article evaluation and data extraction were independently conducted by two reviewers. Results Sixteen articles (6,694 participants)—14 cross-sectional studies and 2 cohort studies—were included in this meta-analysis. The cross-sectional studies demonstrated that ART group did not perform better than the non-ART group ( OR = 1.16; 95% CI, 1.03–1.30). However, the cohort studies reported a significant improvement in cognitive function at three months ( OR = 4.01; 95% CI , 2.35–6.85) and six months ( OR = 9.24; 95% CI, 1.71–49.96) after ART initiation compared with the baseline data. No significant cognitive improvement was found in participants younger than 55 years old, but the two cross-sectional studies showed that ART may improve cognitive function in PLWH under 65 years old with poor physical condition and immune status. Conclusions ART could improve cognitive function in PLWH with poor physical condition and immune status, but it does not considerably improve cognition in the entire PLWH population.

show abstract

Section: Discussionmentioning

confidence: 99%

Antiretroviral therapy improves neurocognitive impairment in people living with HIV? A meta-analysis

Gao

Meng

Xiao

et al. 2020

International Journal of Nursing Sciences

View full text Add to dashboard Cite

show abstract

“…The 6 m was measured in the middle section of a 10-m walk and repeated 3 times to calculate an average. In a previous study in 2016, normative data had been collected in medical outpatient population at MRRH ( n = 85) assumed to be representative of a Tanzanian population and age and education matched, and HIV negative (Paddick et al 2017 ). Walking speed more than 1 standard deviation (SD) below the mean was deemed slow.…”

Section: Walking Speedmentioning

confidence: 99%

Low levels of frailty in HIV-positive older adults on antiretroviral therapy in northern Tanzania

et al. 2021

View full text Add to dashboard Cite

There are over 3 million people in sub-Saharan Africa (SSA) aged 50 and over living with HIV. HIV and combined antiretroviral therapy (cART) exposure may accelerate the ageing in this population, and thus increase the prevalence of premature frailty. There is a paucity of data on the prevalence of frailty in an older HIV + population in SSA and screening and diagnostic tools to identify frailty in SSA. Patients aged ≥ 50 were recruited from a free Government HIV clinic in Tanzania. Frailty assessments were completed, using 3 diagnostic and screening tools: the Fried frailty phenotype (FFP), Clinical Frailty Scale (CFS) and Brief Frailty Instrument for Tanzania (B-FIT 2). The 145 patients recruited had a mean CD4 + of 494.84 cells/µL, 99.3% were receiving cART and 72.6% were virally suppressed. The prevalence of frailty by FFP was 2.758%. FFP frailty was significantly associated with female gender (p = 0.006), marital status (p = 0.007) and age (p = 0.038). Weight loss was the most common FFP domain failure. The prevalence of frailty using the B-FIT 2 and the CFS was 0.68%. The B-FIT 2 correlated with BMI (r = − 0.467, p = 0.0001) and CD4 count in females (r = − 0.244, p = 0.02). There is an absence of frailty in this population, as compared to other clinical studies. This may be due to the high standard of HIV care at this Government clinic. Undernutrition may be an important contributor to frailty. It is unclear which tool is most accurate for detecting the prevalence of frailty in this setting as levels of correlation are low.

show abstract

Prevalence of HIV-associated neurocognitive impairment (hand) amongst adults aged 50 and over attending a HIV clinic in Northern Tanzania

Cited by 2 publications

References 0 publications

Antiretroviral therapy improves neurocognitive impairment in people living with HIV? A meta-analysis

Antiretroviral therapy improves neurocognitive impairment in people living with HIV? A meta-analysis

Low levels of frailty in HIV-positive older adults on antiretroviral therapy in northern Tanzania

Contact Info

Product

Resources

About